CD8A and neoplasm: Our observations indicate that in CD8+ T cell-resistant tumors, activation of NK cells may lead to inhibition of tumor growth and in the case of such tumors, treatment with immune checkpoint inhibitors could be ineffective, which is consistent with our previous results that show no additional benefits of using the PD-1 inhibitor in tumors with suppressed CD8+PD-1+ T cell level [5].